Program
Partially Engineered T-regulatory Cell Donor Graft TRGFT-201
Its studies are mostly in Leukemia, Myeloid, Acute, led by Orca Biosystems.
Furthest: phase 3, since Mar 30, 20223 company-led studies, 3 open or runningNext primary completion: Nov 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Orca Biosystems | 33 open or running | phase 3since Mar 30, 2022 | Jul 3, 2019 | Nov 2027phase 2 · NCT07216443 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2019First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT04013685 · 155 enrolled · United States
- Mar 30, 2022Phase 3 study in Leukemia, Myeloid, AcuteNCT05316701 · 187 enrolled · United States
- Sep 29, 2025Phase 2 study in Leukemia, Myeloid, AcuteNCT07216443 · 80 planned · United States
Ahead
- Nov 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT07216443
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07216443Leukemia, Myeloid, Acute · United States | 2 | Recruiting | Nov 2027 | 80 |
| NCT05316701Leukemia, Myeloid, Acute · United States | 3 | Active, not recruiting | Jul 15, 2024 | 187 |
| NCT04013685Leukemia, Myeloid, Acute · United States | 1 | Active, not recruiting | Apr 30, 2025 | 155 |
How it is read
Names in the registry
- “Orca-T”, 3 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.